Lyell Immunopharma Business Summary

Lyell Immunopharma, Inc. (LYEL) is a clinical-stage biotechnology company that generates revenue primarily through strategic research collaborations, licensing agreements, and equity financing, as it has not yet commercialized its therapeutic pipeline. The company operates through a single business segment focused on the development of next-generation adoptive T-cell therapies designed to overcome T-cell exhaustion and lack of durable stemness in solid and hematologic malignancies. Its lead clinical asset, rondecabtagene autoleucel (ronde-cel, formerly LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy currently in Phase 3 pivotal trials for large B-cell lymphoma. Lyell competes directly with established cell therapy leaders and emerging biotechs such as Kite Pharma (Gilead), Arcellx, Autolus Therapeutics, and Juno Therapeutics (Bristol Myers Squibb), positioning itself as a late-stage clinical innovator aiming to deliver best-in-class durability and response rates through its proprietary ex vivo genetic and epigenetic reprogramming technologies. The company was founded by a distinguished team of cell therapy pioneers, including Rick Klausner, M.D. (former Director of the National Cancer Institute and co-founder of Juno Therapeutics), Crystal Mackall, M.D. (Stanford University Professor and pediatric oncology expert), and Stan Riddell, M.D. (Fred Hutchinson Cancer Center investigator). The current executive leadership team is led by President and CEO Lynn Seely, M.D., who also serves as Interim Principal Financial Officer following the 2025 retirement of Charles Newton. Other key executives include Chief Scientific Officer Gary Lee, Ph.D., Chief Operating Officer Stephen Hill, M.B.A., and Chief Medical Officer David Shook, M.D. Lyell is backed by high-profile institutional investors and partners, most notably GSK, ARCH Venture Partners (represented on the board by Robert Nelsen), and Sahsen Ventures, maintaining a robust cash runway supported by a $100 million private placement completed in late 2025.